10-K: Connect Biopharma Reports Increased Losses, Advances Rademikibart Trials

Connect Biopharma reported a significant increase in net loss for 2025, while advancing its lead drug candidate, rademikibart, into Phase 2 trials for acute asthma and COPD, and securing a private placement for additional funding.

Summary

• Net loss for the year ended December 31, 2025, increased to $55.5 million, up from $15.6 million in 2024.
• Cash, cash equivalents, and short-term investments decreased to $44.3 million as of December 31, 2025, from $93.7 million in 2024.
• Initiated two Phase 2 trials for rademikibart in May 2025, targeting acute exacerbations of asthma (Seabreeze STAT ASTHMA) and COPD (Seabreeze STAT COPD), with topline data expected in mid-2026.
• Announced positive topline data from a Phase 1 clinical pharmacology study of IV rademikibart in March 2026, showing rapid and sustained improvement in FEV1 in asthma and COPD patients.
• Simcere Pharmaceutical Co., Ltd., Connect Biopharma's partner in Greater China, submitted a New Drug Application for rademikibart for atopic dermatitis (AD) to the NMPA of China in July 2025.
• Simcere also announced positive topline data from a Phase 3 study of rademikibart in moderate-to-severe AD in March 2026, demonstrating rapid, durable efficacy and a favorable safety profile.
• Received $21 million upfront and $6.5 million in development milestones and cost reimbursements from the Simcere License Agreement, with potential for up to $110 million in remaining milestone payments.
• Entered into a private placement in March 2026 to sell 6.1 million ordinary shares for gross proceeds of $20.2 million, with net proceeds estimated at $18.6 million.
• Relocated corporate headquarters to San Diego, California, in February 2025, with a lease expiring January 31, 2028.
• Maintains an operating lease for laboratory and office space in Taicang, China, extended until April 30, 2027.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While significant clinical progress and a successful capital raise are positive, the substantial increase in net loss and cash burn, coupled with the lapse of a milestone payment, indicate ongoing financial challenges and a high-risk profile for a clinical-stage company.

Positives

• Initiation of two Phase 2 trials for rademikibart in acute asthma and COPD, addressing significant unmet medical needs.
• Positive topline data from the Phase 1 IV rademikibart study, demonstrating rapid FEV1 improvement and a potentially differentiated bronchodilation effect.
• FDA alignment on the design of the two parallel Phase 2 acute exacerbation trials for asthma and COPD.
• Successful partnership with Simcere Pharmaceutical Co., Ltd. for Greater China, including $27.5 million received in upfront and milestone payments, with potential for an additional $110 million.
• Simcere's submission of a New Drug Application for rademikibart in Atopic Dermatitis in China.
• Positive Phase 3 data for rademikibart in moderate-to-severe Atopic Dermatitis from Simcere's study, showing rapid, durable efficacy and lower conjunctivitis rates compared to other agents in its class.
• Preclinical data supporting rademikibart's potentially differentiated efficacy and safety profile, with enhanced IL-4R inhibition compared to dupilumab.
• Successful private placement raising $20.2 million gross proceeds, extending the company's cash runway.

Negatives

• Significant increase in net loss to $55.5 million in 2025 from $15.6 million in 2024.
• Decrease in cash, cash equivalents, and short-term investments from $93.7 million in 2024 to $44.3 million in 2025.
• License and collaboration revenues decreased significantly from $26.0 million in 2024 to $0.1 million in 2025.
• Research and development expenses increased to $37.8 million in 2025 from $29.3 million in 2024.
• Other income, net, decreased to $2.8 million in 2025 from $7.0 million in 2024, primarily due to lower government subsidies and interest income.
• One time-based milestone payment of approximately $8 million from the Simcere License Agreement lapsed in 2025 due to not being achieved by the deadline.
• The company has a limited operating history and has incurred significant operating losses since inception, with no guarantee of future profitability.
• Existing capital is not sufficient to fund product candidates through regulatory approval, requiring substantial additional financing.

Risks

• Limited operating history and significant operating losses since inception, with no guarantee of future profitability.
• Requirement for substantial additional financing to achieve goals; failure to obtain capital could delay or terminate product development and commercialization.
• Clinical drug development is a lengthy, expensive, and uncertain process, with potential for unforeseen costs or delays.
• Dependence on patient enrollment in clinical trials, which could experience delays or difficulties.
• Product candidates may be associated with serious adverse events or undesirable side effects, potentially delaying or preventing regulatory approval or limiting commercial potential.
• Reliance on third parties (CROs, manufacturers) to conduct preclinical studies, clinical trials, and manufacturing, increasing risks of delays, insufficient quantities, or non-compliance.
• Commercial success depends on market acceptance by physicians, patients, and healthcare payors, and favorable pricing/reimbursement policies.
• Increasing use of AI and machine learning in drug discovery introduces new and evolving risks, including flawed results, increased costs, and intellectual property challenges.
• Dependence on key management and scientific personnel; inability to retain or recruit additional personnel could harm the business.
• Significant changes in U.S. or PRC laws/policies (e.g., trade, tariffs, data security) could materially and adversely affect business and operations.
• Uncertainty in PRC laws and regulations, which can be vague and subject to inconsistent interpretation, potentially impacting operations and share value.
• Potential for classification as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. holders.
• Difficulties for investors in protecting interests or enforcing non-PRC judgments due to Cayman Islands incorporation and PRC legal system differences.
• Inflationary pressures and uncertain availability/prices of raw materials or logistics could negatively impact operations and clinical trials.
• Vulnerability to natural disasters, terrorism, or public health epidemics, especially with single-site suppliers.
• Risk of product liability lawsuits, potentially leading to substantial liabilities or commercialization limitations.
• IT systems, or those of third parties, may fail or suffer security breaches, disrupting operations or compromising sensitive information.
• Employees and independent contractors may engage in misconduct or improper activities, leading to noncompliance with regulatory standards.
• Strategic transactions (acquisitions, licenses) could impact liquidity, increase expenses, and distract management.
• Inability to protect intellectual property rights globally, including in the U.S., Europe, and the PRC, due to varying legal protections and enforcement challenges.
• Potential for compulsory standards for remuneration to creators or inventors of patents under PRC laws, leading to considerable costs.
• Fluctuations in currency exchange rates, particularly Renminbi against the U.S. dollar, may adversely affect financial results.
• Risk of delisting from Nasdaq if continued listing requirements are not met.
• Concentration of ownership by executive officers, directors, and principal shareholders, potentially delaying or preventing a change of control.
• Uncertainty regarding the impact of the EU Pharma Law Review on the regulatory framework for medicinal products in the EU.
• Potential for CFIUS review of foreign investments in the U.S. portion of the business, which could delay or block transactions.

Future Outlook

The company expects research and development expenses to increase in 2026 to support the completion of ongoing Phase 2 clinical trials for rademikibart. Topline data for these acute exacerbation studies in asthma and COPD is anticipated in mid-2026. The company will require substantial additional financing to fund product candidates through regulatory approvals and commercialization, and is actively seeking collaborations and other financing sources. The company expects its current cash, cash equivalents, and short-term investments, including proceeds from the recent private placement, to fund operations for at least one year from the filing date of this report.

Management Comments

• "Rademikibart is a next-generation, potentially best-in-class antibody designed to target interleukin-4-receptor alpha (IL-4R)."
• "If rademikibart were approved for the treatment of acute asthma, a significant percentage of asthma patients treated acutely with rademikibart would remain on it chronically."
• "Rademikibart, if approved, would offer the opportunity for significant healthcare cost savings by potentially reducing the length of stay for admitted asthma patients, as well as potentially reducing the frequency of emergency department re-visits and rehospitalizations."
• "The rapid improvement in FEV1 demonstrated with IV rademikibart in this study provides clinical confirmation of preclinical observations that rademikibart has a unique beneficial effect on bronchodilation."
• "Our current development plan is supported by the results from the completed global asthma trial CBP-201-WW002."
• "Our clinical development program is focused on the potential of rademikibart for faster onset of action and greater clinical response, with a potentially favorable safety profile."
• "The potential for less frequent dosing than dupilumab will also be explored."
• "Rademikibart has the potential to drive significant chronic utilization in asthma and COPD with an initial focus on acute indications, which represent an untapped opportunity."
• "The AD market in China represents considerable opportunity, with an estimated 70 million patients with AD."
• "We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative space will be available in the future on commercially reasonable terms."
• "Our management, with the participation of our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures... and concluded that our disclosure controls and procedures were effective as of December 31, 2025."
• "Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2025... management concluded that, as of December 31, 2025, our internal control over financial reporting was effective based on those criteria."

Industry Context

StockSavvy.ai notes that Connect Biopharma is operating in the highly competitive and capital-intensive biopharmaceutical industry, particularly in the immunology and inflammation space. The focus on IL-4R alpha inhibition positions rademikibart against established biologics like dupilumab (DUPIXENT). The company's strategy to target acute exacerbations in asthma and COPD represents a potential differentiation in a market with significant unmet needs, as current standard of care often falls short. The increasing use of AI in drug discovery and development is a broader industry trend, and the company acknowledges the associated risks and potential benefits, indicating a forward-looking approach to technology integration. The regulatory landscape, especially in the U.S. and China, continues to evolve with new data security laws and drug pricing reforms, which could impact market access and profitability.

Comparison to Industry Standards

• Rademikibart demonstrated greater FEV1 response than seen in clinical trials of currently approved biologics (e.g., dupilumab) using the initial protocol-specified baseline eosinophils > 150 cells/L, based on cross-study comparisons.
• Rademikibart showed rapid onset of action with the majority of FEV1 increase observed within 24 hours of subcutaneous dose, supporting its potential for acute exacerbations, a feature that could differentiate it from existing chronic therapies.
• Cross-study safety comparison suggests a difference in the safety profile of rademikibart compared to dupilumab for hypereosinophilia events, with rademikibart showing lower conjunctivitis in AD trials.
• Preclinical data indicates rademikibart has enhanced IL-4R inhibition and stronger binding affinity compared to dupilumab, providing a molecular rationale for observed efficacy differences.
• The potential for less frequent dosing than dupilumab is being explored, which could offer a convenience advantage in the market.
• In COPD-like patients, rademikibart improved FEV1 over baseline beginning at week 1 and sustained through 24 weeks, with a 63% average reduction in annual exacerbation rate, suggesting competitive efficacy in this indication.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• Not aware of any pending or threatened legal proceedings that could have an adverse effect on business, operating results, or financial condition.

Related Party Transactions

• No related person transactions exceeding $120,000 or one percent of average total assets were entered into or proposed since January 1, 2025, other than executive officer and non-employee director compensation arrangements.

Stakeholder Impact

• **Shareholders:** Face increased risk due to significant net losses and cash burn, but also potential upside from positive clinical trial data and a recent capital raise. Dilution from the private placement is a factor. PRC regulatory risks and potential for limited enforcement of U.S. securities laws in the Cayman Islands or PRC remain concerns.
• **Employees:** Benefit from competitive compensation, equity incentive plans, and comprehensive benefits. Management changes indicate ongoing organizational evolution, which could impact stability or opportunities.
• **Patients:** Potential for new treatment options for acute asthma, COPD, and atopic dermatitis if rademikibart successfully completes trials and gains regulatory approval, offering faster onset of action and potentially improved safety/efficacy profiles.
• **Partners (e.g., Simcere):** The collaboration with Simcere is progressing with NDA submission and positive Phase 3 data, indicating a strong working relationship and potential for future milestone and royalty payments.
• **Creditors:** The company's liquidity position, while bolstered by the private placement, remains a key consideration given the high cash burn and need for future financing.

Next Steps

• Report topline data for Phase 2 acute exacerbation studies in asthma and COPD in mid-2026.
• Simcere to continue development, manufacturing, and commercialization of rademikibart in Greater China, including pursuing regulatory approval for Atopic Dermatitis.
• Explore the potential for less frequent dosing of rademikibart than dupilumab.
• Continue to evaluate and potentially integrate AI technologies into drug discovery and development.
• Seek additional funding through equity offerings, debt financings, collaborations, monetization transactions, government contracts, or other strategic transactions.
• Comply with new PRC filing rules for future securities offerings, including under the at-the-market offering program.

Key Dates

Recommendation

Connect Biopharma presents a high-risk, high-reward profile. The significant increase in net loss and cash burn, coupled with the lapse of a milestone payment, highlight substantial financial challenges and the inherent risks of clinical-stage biopharmaceutical development. However, the positive Phase 1 IV rademikibart data, the initiation of two Phase 2 trials for acute indications with high unmet needs, and the positive Phase 3 AD data from the Simcere collaboration are strong clinical catalysts. The recent private placement provides a temporary liquidity buffer. Given the early to mid-stage nature of its lead asset's development and the financial pressures, a 'hold' recommendation is appropriate. Investors should monitor the upcoming mid-2026 topline data for the Phase 2 acute exacerbation studies and the progress of Simcere's AD NDA, as these events will be critical in determining the company's future trajectory and potential for long-term value creation.

Keywords

Rademikibart, Asthma, COPD, Atopic Dermatitis, IL-4R antibody, Clinical-stage biopharmaceutical, Phase 2 trials, Drug development, SEC filing, Biologics, Immunology, Inflammation, Nasdaq, Cayman Islands, China, Simcere, Private Placement, Financial reporting, Corporate governance, Risk management